Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
13.49
-0.07 (-0.52%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Viridian Therapeutics stock have an average target of 36.44, with a low estimate of 20 and a high estimate of 61. The average target predicts an increase of 170.13% from the current stock price of 13.49.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +152.04% | Apr 23, 2025 |
| Needham | Needham | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +181.69% | Jan 7, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $27 | Buy → Hold | Downgrades | $27 | +100.15% | Dec 19, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $44 → $47 | Buy | Maintains | $44 → $47 | +248.41% | Dec 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $34 | Strong Buy | Reiterates | $34 | +152.04% | Dec 17, 2024 |
Financial Forecast
Revenue This Year
198.29K
from 302.00K
Decreased by -34.34%
Revenue Next Year
40.95M
from 198.29K
Increased by 20,553.29%
EPS This Year
-4.08
from -3.07
EPS Next Year
-3.95
from -4.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1M | 96.9M | 1.0B | ||
| Avg | 198,288 | 41.0M | 311.3M | ||
| Low | n/a | n/a | 102.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 247.7% | 48,775.9% | 2,415.1% | ||
| Avg | -34.3% | 20,553.3% | 660.2% | ||
| Low | - | - | 151.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.36 | -2.87 | 3.96 | ||
| Avg | -4.08 | -3.95 | -1.71 | ||
| Low | -5.28 | -4.85 | -3.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.